MedTrace Logo

First-in-human Study of SAN711 in Healthy Participants

NCT04971135 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-07-21

No results posted yet for this study

Summary

Phase 1, first-in-human, double-blind, randomized, placebo-controlled, parallel group, single ascending dose (SAD) and multiple ascending dose (MAD) study

Conditions

  • Healthy

Interventions

DRUG

SAN711

SAN711 liquid formulation

OTHER

Placebo

Matching placebo

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Saniona

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04971135 on ClinicalTrials.gov